How should we evaluate the cost-effectiveness of CAR T-cell therapies?

Overview of attention for article published in Health Policy and Technology, September 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 9 X posts from 6 X users, with an upper bound of 5,456 followers.

RT @FutureHealthHub: Read our paper "How should we evaluate the cost-effectiveness of CAR T-cell therapies?" here: https://t.co/mvY1nXK3rH…

RT @FutureHealthHub: Read our paper "How should we evaluate the cost-effectiveness of CAR T-cell therapies?" here: https://t.co/mvY1nXK3rH…

RT @FutureHealthHub: Read our paper "How should we evaluate the cost-effectiveness of CAR T-cell therapies?" here: https://t.co/mvY1nXK3rH…

RT @FutureHealthHub: Read our paper "How should we evaluate the cost-effectiveness of CAR T-cell therapies?" here: https://t.co/mvY1nXK3rH…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.